Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AMRX

AMRX - Amneal Pharmaceuticals Inc Stock Price, Fair Value and News

5.73USD-0.05 (-0.87%)Market Closed
Watchlist

Market Summary

USD5.73-0.05
Market Closed
-0.87%

AMRX Stock Price

View Fullscreen

AMRX RSI Chart

AMRX Valuation

Market Cap

878.8M

Price/Earnings (Trailing)

86.88

Price/Sales (Trailing)

0.37

EV/EBITDA

14.97

Price/Free Cashflow

6.2

AMRX Price/Sales (Trailing)

AMRX Profitability

EBT Margin

1.49%

Return on Equity

3.06%

Return on Assets

0.27%

Free Cashflow Yield

16.12%

AMRX Fundamentals

AMRX Revenue

Revenue (TTM)

2.4B

Rev. Growth (Yr)

13.65%

Rev. Growth (Qtr)

3.5%

AMRX Earnings

Earnings (TTM)

10.1M

Earnings Growth (Yr)

304.12%

Earnings Growth (Qtr)

-30.1%

Breaking Down AMRX Revenue

Last 7 days

5.9%

Last 30 days

9.3%

Last 90 days

30.2%

Trailing 12 Months

157.6%

How does AMRX drawdown profile look like?

AMRX Financial Health

Current Ratio

1.91

Debt/Equity

7.68

Debt/Cashflow

0.07

AMRX Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

0.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.3B2.3B2.4B0
20222.1B2.1B2.1B2.2B
20212.0B2.1B2.1B2.1B
20201.7B1.7B1.9B2.0B
20191.8B1.8B1.7B1.6B
20181.1B1.2B1.5B1.7B
20171.0B1.0B1.0B1.0B
20160001.0B

Tracking the Latest Insider Buys and Sells of Amneal Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 01, 2024
patel gautam
gifted
-
-
1,598,120
-
Jan 01, 2024
patel gautam
sold
-
-
-33,458,100
-
Nov 07, 2023
patel dipan
acquired
-
-
26,905,100
-
Nov 07, 2023
patel chirag k.
acquired
-
-
21,269,400
president & co-ceo
Nov 07, 2023
patel chintu
acquired
-
-
24,753,300
co-ceo
Nov 07, 2023
patel gautam
acquired
-
-
17,497,300
-
Nov 07, 2023
patel tushar bhikhubhai
acquired
-
-
53,578,200
-
Aug 11, 2023
boyer andrew s
sold
-120,921
4.1267
-29,302
executive vice president
Jul 30, 2023
autor deborah m.
acquired
-
-
54,949
-
Jun 30, 2023
boyer andrew s
acquired
-
-
23,095
executive vice president

1–10 of 50

Which funds bought or sold AMRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-28.27
4,588
164,588
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.63
150,000
463,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-97,000
-
-%
Feb 15, 2024
State of Wyoming
added
11.09
183,377
490,074
0.09%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
55.00
55.00
-%
Feb 15, 2024
Virtus Investment Advisers, Inc.
unchanged
-
110,464
362,440
0.27%
Feb 15, 2024
BARCLAYS PLC
added
313
1,172,000
1,408,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
10.89
255,292
684,344
-%
Feb 15, 2024
Legal & General Group Plc
added
738
481,132
524,606
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
110
19,001,700
28,339,600
0.85%

1–10 of 47

Are Funds Buying or Selling AMRX?

Are funds buying AMRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMRX
No. of Funds

Unveiling Amneal Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.45%
13,642,387
SC 13G/A
Jan 05, 2024
mahesh akram
9.%
30,384,769
SC 13G
Jan 03, 2024
patel gautam
0.07%
2,025,454
SC 13D/A
Dec 12, 2023
fosun international ltd
5.4%
16,438,356
SC 13G/A
Dec 01, 2023
patel gautam
11.1%
33,885,406
SC 13D/A
Nov 08, 2023
patel gautam
10.0%
30,812,108
SC 13D/A
Nov 08, 2023
patel tushar bhikhubhai
17.5%
53,578,209
SC 13D/A
Nov 08, 2023
patel chintu
8.3%
25,318,839
SC 13D/A
Nov 08, 2023
patel dipan
8.8%
26,905,073
SC 13D/A
Nov 08, 2023
patel chirag k.
7.1%
21,835,007
SC 13D/A

Recent SEC filings of Amneal Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 10, 2024
8-K
Current Report
Jan 05, 2024
SC 13G
Major Ownership Report
Jan 03, 2024
4
Insider Trading
Jan 03, 2024
SC 13D/A
13D - Major Acquisition
Dec 27, 2023
CERT
CERT
Dec 26, 2023
25
25
Dec 26, 2023
8-A12B
8-A12B
Dec 15, 2023
8-K
Current Report
Dec 15, 2023
8-K/A
Current Report

What is the Fair Value of AMRX?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Amneal Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
382.2B
93.0B
-3.60% -2.76%
10.87
4.11
6.46% 95.94%
156.2B
23.6B
-3.76% -37.06%
-118.72
6.62
-28.02% -113.34%
151.9B
28.2B
-7.44% 18.02%
22.62
5.39
7.09% 2.52%
91.2B
27.4B
-17.13% -16.65%
15.53
3.33
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.09
0.92
6.17% 77.01%
MID-CAP
4.9B
1.7B
14.11% 18.79%
13.7
2.93
49.61% 324.78%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.2B
8.5B
-0.23% 18.85%
-3.29
0.37
5.11% -479.13%
2.5B
601.3M
-0.28% 70.16%
18.15
4.08
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.92
1.89
16.26% -147.49%
23.9M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
20.7M
84.1M
58.23% -28.98%
-0.97
0.22
2882.68% -145.15%
17.6M
111.1M
-6.33% -18.68%
-1.1
0.16
-10.43% 84.90%
2.5M
20.0M
-35.83% -91.10%
-0.18
0.12
137.71% 66.04%

Amneal Pharmaceuticals Inc News

Latest updates
Yahoo Finance24 hours ago
StockNews.com12 Feb 202406:00 pm
InvestorsObserver30 Jan 202408:00 am
Seeking Alpha25 Jan 202408:00 am
Business Wire2 months ago

Amneal Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue3.5%620599558610546559498537529535493510519465499397378405446498476
Gross Profit5.7%23322017821519420117516619921219216713414418311054.0010583.00193200
  S&GA Expenses7.0%11310610210210099.0099.0097.0091.0086.0091.0085.0083.0081.0078.0074.0064.0067.0084.0071.0075.00
  R&D Expenses9.5%41.0038.0039.0042.0050.0051.0053.0052.0049.0053.0048.0053.0045.0046.0036.0048.0038.0048.0054.0057.0042.00
EBITDA Margin14.2%0.09*0.08*-0.04*-0.05*-0.06*-0.07*0.06*0.07*0.08*0.07*0.05*0.05*0.03*0.06*0.05*-0.04*-0.01*-0.01*-0.13*-0.04*-0.01*
Interest Expenses0.5%48.0048.0041.0051.0035.0030.0027.0030.0030.0032.0030.0031.0031.0033.0035.0037.0041.0041.0040.0042.0039.00
Income Taxes-8926.1%-2.08-0.021.00-1.765.007.00-3.464.004.003.000.002.000.002.00-1088.00390-5.70-8.436.005.00
Earnings Before Taxes-22.6%23.0030.00-9.43-7.652.00-232-9.92-16.32-2.0435.0015.00-5.48-21.89-21.7613.00-57.1126.00-56.23-133-14.8123.00
EBT Margin133.3%0.01*0.01*-0.11*-0.11*-0.12*-0.12*0.00*0.01*0.02*0.01*-0.02*-0.02*-0.05*-0.02*-0.04*-0.14*-0.10*-0.10*-0.21*-0.12*-0.09*
Net Income-30.1%16.0022.00-15.63-12.03-7.61-242-8.82-21.80-7.7830.0013.00-6.83-21.64-24.16120-64.90-265-16.90-47.88-20.3317.00
Net Income Margin175.2%0.00*-0.01*-0.12*-0.12*-0.13*-0.13*0.00*0.01*0.01*0.01*-0.02*0.03*0.01*-0.13*-0.13*-0.24*-0.20*-0.04*-0.16*-0.24*-0.23*
Free Cashflow398.6%70.00-23.35130-34.7674.00-13011046.0072.00-59.7413676.0034.0017142.00-55.411279.00-12624036.00
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.4%3,6873,7013,6273,7993,8744,0413,8893,9403,9744,0233,9604,0064,0384,0574,3913,6663,7044,2624,3854,3534,582
  Current Assets2.4%1,4561,4221,3071,4121,4201,5541,3901,5201,5701,5631,5601,5521,5441,4811,7741,2101,2061,1861,2681,2871,431
    Cash Equivalents-20.5%87.0010914526.0087.0092.0021025730327845234128126640515321355.0064.00219165
  Inventory4.7%576551529531544533512489520523497491476444438381402415448457491
  Net PPE-1.6%452459463470470484501514460468471478462461468478491508514544567
  Goodwill-0.1%59959959959960060160359356654944.00523523527515420420420422426411
  Current Liabilities-2.2%761777704753818993602677667673637677668655965550535546600554749
  Long Term Debt-0.3%2,5422,5492,5622,5922,6072,6222,6732,6802,6882,7202,7282,7352,7572,7652,7722,6092,6142,6202,6252,6312,675
    LT Debt, Current0.4%31.0030.0030.0030.0030.0030.0031.0031.0030.0030.0030.0044.00---------
    LT Debt, Non Current-0.3%2,5422,5492,5622,5922,6072,6222,6732,6802,6882,7202,7282,7352,7572,7652,7722,6092,6142,6202,6252,631-
Shareholder's Equity119.4%331151135298194173407367383390367345348371403347396749800896915
  Retained Earnings2.4%-391-401-413-406-401-399-278-276-269-265-280-286-283-274-262-377-345-80.75-63.84-20.92-12.15
  Additional Paid-In Capital1.0%715708701692684676667658651643634628623618612607566544537530520
Shares Outstanding-0.2%153154152151151151150149149149148147148147147132129128128127127
Minority Interest-5.5%-176-167-159-114-103-10716.007.0033.0044.0044.0042.0047.0065.0085.00115178290328392414
Float------471---751---696---1,202---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations817.4%81.00-11.34140-23.2994.00-12512063.0082.00-51.9314810645.0017949.00-50.8914021.00-10826062.00
  Share Based Compensation2.0%7.007.008.008.008.008.008.008.008.008.005.005.005.006.005.005.006.006.004.004.004.00
Cashflow From Investing-9.7%-13.48-12.28-11.74-11.47-49.33-16.12-97.39-86.97-11.63-82.89-12.69-31.79-14.78-8.93-262-4.7730.00-23.33-21.475.00-40.77
Cashflow From Financing-606.5%-86.58-12.26-12.90-22.17-46.1323.00-61.57-30.35-43.55-38.07-26.15-11.28-14.81-310468-7.30-7.60-9.07-21.86-21883.00
  Dividend Payments----------------------

AMRX Income Statement

2023-09-30
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net revenue$ 620,040$ 545,557$ 1,776,626$ 1,602,545
Cost of goods sold387,509351,3271,145,8881,033,225
Gross profit232,531194,230630,738569,320
Selling, general and administrative113,006100,071320,672297,542
Research and development41,37550,235117,864153,781
Intellectual property legal development expenses8861,4113,3502,996
Acquisition, transaction-related and integration expenses0390714
Restructuring and other charges1,0435811,6351,312
Change in fair value of contingent consideration3,120(1,425)(787)(1,495)
Insurance recoveries for property losses and associated expenses000(1,911)
(Credit) charges related to legal matters, net(2,620)285(1,039)249,836
Other operating expense (income)73(1,320)(1,138)(2,495)
Operating income (loss)75,64844,353190,181(130,960)
Other (expense) income:    
Interest expense, net(50,909)(42,391)(151,081)(111,349)
Foreign exchange loss, net(2,939)(5,491)(617)(12,933)
Other income, net1,1575,7094,70814,770
Total other expense, net(52,691)(42,173)(146,990)(109,512)
Income (loss) before income taxes22,9572,18043,191(240,472)
(Benefit from) provision for income taxes(2,076)4,570(1,431)8,459
Net income (loss)25,033(2,390)44,622(248,931)
Less: Net (income) loss attributable to non-controlling interests(15,351)(299)(29,966)123,716
Net income (loss) attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest9,682(2,689)14,656(125,215)
Accretion of redeemable non-controlling interest000(438)
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.$ 9,682$ (2,689)$ 14,656$ (125,653)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:    
Basic (in dollars per share)$ 0.06$ (0.02)$ 0.10$ (0.83)
Diluted (in dollars per share)$ 0.06$ (0.02)$ 0.09$ (0.83)
Weighted-average common shares outstanding:    
Basic (in shares)154,219151,393153,363150,765
Diluted (in shares)159,691151,393156,284150,765

AMRX Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 86,929$ 25,976
Restricted cash8,6789,251
Inventories576,474530,735
Prepaid expenses and other current assets91,444103,565
Total current assets1,456,0751,411,818
Property, plant and equipment, net451,852469,815
Goodwill598,631598,853
Intangible assets, net982,5311,096,093
Other assets89,043103,217
Total assets3,687,0793,799,341
Current liabilities:  
Current portion of liabilities for legal matters76,828107,483
Revolving credit facilities76,00060,000
Current portion of long-term debt, net30,53329,961
Total current liabilities760,601752,800
Long-term debt, net2,541,8142,591,981
Note payable - related party41,00139,706
Total long-term liabilities2,735,0982,837,613
Commitments and contingencies (Notes 5 and 19)
Redeemable non-controlling interests37,14424,949
Stockholders' Equity  
Preferred stock, $0.01 par value, 2,000 shares authorized, none issued at both September 30, 2023 and December 31, 202200
Additional paid-in capital715,450691,629
Stockholders' accumulated deficit(391,527)(406,183)
Accumulated other comprehensive income3,8739,939
Total Amneal Pharmaceuticals, Inc. stockholders' equity330,860298,421
Non-controlling interests(176,624)(114,442)
Total stockholders' equity154,236183,979
Total liabilities and stockholders' equity3,687,0793,799,341
Related Party  
Current assets:  
Trade accounts receivable, net1,603500
Operating lease right-of-use assets15,87617,910
Current liabilities:  
Accounts payable and accrued expenses3,5002,479
Current portion of operating lease liabilities - related party3,0552,869
Operating lease liabilities13,59815,914
Other long-term liabilities11,5349,649
Nonrelated Party  
Current assets:  
Trade accounts receivable, net690,947741,791
Operating lease right-of-use assets32,52338,211
Financing lease right-of-use assets60,54863,424
Current liabilities:  
Accounts payable and accrued expenses557,761538,199
Current portion of operating lease liabilities9,8268,321
Current portion of financing lease liabilities3,0983,488
Operating lease liabilities26,41232,126
Financing lease liabilities59,35160,769
Other long-term liabilities41,38887,468
Class A Common Stock  
Stockholders' Equity  
Common stock1,5421,514
Class B Common Stock  
Stockholders' Equity  
Common stock$ 1,522$ 1,522
AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
 CEO
 WEBSITEamneal.com
 EMPLOYEES7600

Amneal Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Amneal Pharmaceuticals Inc? What does AMRX stand for in stocks?

AMRX is the stock ticker symbol of Amneal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amneal Pharmaceuticals Inc (AMRX)?

As of Wed Feb 21 2024, market cap of Amneal Pharmaceuticals Inc is 878.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers. The fair value of Amneal Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amneal Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amneal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMRX is over valued or under valued. Whether Amneal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amneal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRX.

What is Amneal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, AMRX's PE ratio (Price to Earnings) is 86.88 and Price to Sales (PS) ratio is 0.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRX PE ratio will change depending on the future growth rate expectations of investors.